As employers face mounting pressure to improve health outcomes while managing rising costs, a new report sponsored by Quantum ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

Manufacturer Lilly has announced plans to hike the amount it charges private providers in the UK to bring it into line with ...

This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

Surging medical costs, pricey new drugs, and the looming end of enhanced subsidies could push ACA Marketplace premiums to ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...